Target
PTEN
43 products, 13 indications
Indications
Metastatic Castration-Resistant Prostate Cancer (23 products)
metastatic hormone sensitive prostate cancer (7 products)
Prostate cancer (6 products)
metastatic castration-sensitive prostate cancer (6 products)
recurrent prostate cancer (5 products)
Advanced or metastatic prostate cancer (5 products)
non-metastatic castration-resistant prostate cancer (2 products)
de novo metastatic castration-sensitive prostate cancer (2 products)
De novo metastatic castration-sensitive prostate cancer (mCSPC) (1 products)
Low-risk prostate cancer (1 products)
PSA-recurrent, non-metastatic, non-castrate prostate cancer (1 products)
metastatic hormone-resistant prostate cancer (1 products)
Metastatic Cancer (1 products)
Loading...
1 drug
53 abstracts
Abstract
FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers.Org: US Medical Affairs Oncology,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.Org: Azienda Ospedaliera Universitaria Pisana, Veneto Institute of Oncology - IRCCS, San Bortolo General Hospital, CRO Aviano, Fondazione Poliambulanza,
Abstract
Association of germline HSD3B1 (c.1100) genotype with tumoral and clinical outcomes in breast and endometrial cancers.Org: University of South Carolina,
Abstract
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Pathology, SUNY Upstate Medical University,
Abstract
Concordance between tissue (tumor DNA) and liquid (ctDNA) biopsy next-generation sequencing (NGS) data in detection of PIK3CA, AKT1, and PTEN alterations in breast cancer: A retrospective analysis.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, AstraZeneca, Gaithersburg, MD,
Abstract
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,
Abstract
Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2- metastatic breast cancer (mBC) in the US.Org: AstraZeneca, Gaithersburg, MD, MD Anderson Cancer Center, PLC, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC.Org: Pune, Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, Cupertino, CA,
Abstract
Investigation of leptomeningeal disease in high grade glioma and characterization of molecular alterations.Org: Caris Life Sciences, Irving, TX, Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Levine Cancer Institute,
Abstract
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Guardant Health, Inc., Palo Alto, CA, Redwood City, CA,
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
Comprehensive characterization of androgen receptor expression in breast cancer.Org: Caris Life Sciences, Irving, TX, City of Hope National Medical Center, Washington University School of Medicine in St Louis, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
Comprehensive profiling of mutational signatures and machine learning and subtypes of homologous recombination deficiency.Org: Genome Insight Inc., Research Institute for Future Medicine, Division of Breast Surgery, Division of Breast and Endocrine Surgery, Samsung Medical Center,
Abstract
The clinical feasibility of circulating tumor DNA alterations in patients with advanced hepatocellular carcinoma.Org: Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, CHA Bundang Medical Center, CHA University School of Medicine, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Medical Oncology Group,
Abstract
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).Org: H. Lee Moffitt Cancer Center and Research Institute, Vita-Salute San Raffaele University, Saint Louis University Hospital, University of Washington; Fred Hutchinson Cancer Center, SUNY Upstate Medical University,
Abstract
Genetic ancestry associations with somatic mutations in a real-world cohort of over 3,000 patients with prostate cancer.Org: Tempus Labs, Inc., Tempus AI, University of Southern California Marshall School of Business,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Identification of biomarkers for early progression in muscle invasive bladder cancer (MIBC) using real-world data.Org: ConcertAI,
Abstract
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).Org: Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain, Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Hospital Clínic de Barcelona, Barcelona, Spain, Hospital Clínic Barcelona, Barcelona, Spain, Hospital Clinic de Barcelona, Barcelona, Spain,
Abstract
Exosome-based delivery of microRNAs to confer adriamycin-resistance to sensitive cells through modulating the immune- and metabolism-related gene PTEN in HER2-negative breast cancer.Org: Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, The First Affiliated Hospital with Nanjing Medical University,
Abstract
Disparities in minority patients with breast cancer under 40 years of age: A single center experience.Org: UT Austin Dell Medical School, Ascension Seton,
Abstract
Comprehensive genomic profiling of Taiwanese patients with breast cancer using a novel targeted panel: Preliminary analyses from a prospective triple-negative cohort.Org: Taipei Veterans General Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).Org: Cliniques Universitaires Saint-Luc, Department of Drug Development and Innovation (D3i), Institut Curie, Saint Cloud, France, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development,
Abstract
Validation of a breast cancer polygenic risk score in 15,490 Brazilians using exome sequencing.Org: Mendelics, Instituto D’Or de Pesquisa e Ensino (IDOR), Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, The University of Chicago Medicine Center for Advanced Care at Orland Park, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL,
Abstract
Commercial next generation sequencing in a real-world cohort of patients with metastatic breast cancer.Org: Renaissance School of Medicine at Stony Brook University, Stony Brook University Hospital - Cancer Center,
Abstract
Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Prevalence and characteristics analysis of CDKN2A/B deletion in glioma.Org: Huashan Hospital Fudan University, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
A pilot study evaluating somatic mutational burden and signatures among endometrial cancer patients: Is there prognostic benefit to whole genome sequencing?Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Nykode Therapeutics, Cornell University, Morehouse School of Medicine,
Abstract
Molecular profile of SWI/SNF complex in Chinese patients with ovarian cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd Nanjing, China, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Somatic hereditary gene panel analysis: A pilot study from Uzbekistan.Org: Vita Alliance Hospital, Tashkent, Uzbekistan,
Abstract
Clinical implications of recurring mutations in myxoid liposarcoma (MLS).Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.Org: Hospital Privado Universitario de Córdoba, CIMETSA-IUCBC,
Abstract
Homologous recombination-related (HRR) gene mutations in patients with glioma and their relevance to genomic characteristics, tumor mutation burden (TMB), and prognosis.Org: Jinan, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Mutation profiling of gliomas based on sex, age, and family history.Org: Shenzhen Longgang Third People's Hospital, Shenzhen, China, Haplox biotechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biottechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China, HaploX Biotechnology Co., Ltd, Shenzhen, Guangdong, China, Tianjin Union Medical Center, Tianjin, Tianjin, China, Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China,
Abstract
Clinical and genomic characteristics between DDR germline and somatic mutations in pan-cancer.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Spectrum of germline pathogenic variants among patients with cancer in Mexico.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico, National Institute of Medical Sciences and Nutrition Salvador Zubirán, City of Hope National Medical Center, Latin American School of Oncology,
Abstract
Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA, PainReform,
Abstract
Utilization and barriers to genomic profiling in breast cancer treatment among oncologists.Org: Cardinal Health, Cardinal Health, LLC, Cardinal Health Specialty Solutions,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Increasing targeted therapy options for mCRPC patients using multigene NGS panel.Org: Genekor Medical SA, Genekor Medical S.A., Naval & Veterans Hospital of Athens/Hellenic Navy, Psychiko Medical Center, Tansan Onkoloji,
Abstract
A survey on the detection of HPD-related genes by liquid biopsy in patients with lung cancer in China.Org: Tianjin Medical University General Hospital, Tianjin, China, HaploX Biotechnology, Shenzhen, China, HaploX Biotechnology Co. Ltd.,
Abstract
Impact of BAP1 mutational status on immunotherapy outcomes in advanced malignant pleural mesothelioma: A single institution experience.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Comprehensive analysis of the mutational status of early colon cancer: Real world data from the AIO ColoPredict registry study.Org: Institut für Pathologie, Georgius Agricola Stiftung Ruhr, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Oncology and Palliative Care Units, Ruhr-University Bochum,
Abstract
Mutational profiling of true single circulating tumor cells (sCTC) in metastatic lung cancer to determine genomic heterogeneity and drug-resistance signatures.Org: OneCell Diagnostics, Cupertino, CA, OneCell Dx, Pune, Tata Memorial Hospital (HBNI),
Abstract
Transformation of tissue-resident, very small embryonic-like stem cells (VSELs) into cancer stem cells (CSCs) and its role in cancer initiation via epigenetic changes.Org: Epigeneres Biotech Pvt. Ltd., National Institute for Research in Reproductive and Child Health,
Abstract
Real-world genetic testing patterns in metastatic prostate cancer in Latin American (LATAM) population.Org: Instituto Alexander Fleming, Fundación Cancer - Fuca, Hospital Italiano de Buenos Aires, Sociedad de Oncología y Hematología del Cesar SOHEC, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,